- Home
- EMN vs RYTM Comparison
EMN vs RYTM Comparison
Compare EMN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMN
- RYTM
- Stock Information
- Founded
- EMN 1920
- RYTM 2008
- Country
- EMN United States
- RYTM United States
- Employees
- EMN N/A
- RYTM N/A
- Industry
- EMN Major Chemicals
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- EMN Industrials
- RYTM Health Care
- Exchange
- EMN Nasdaq
- RYTM Nasdaq
- Market Cap
- EMN 7.2B
- RYTM 6.4B
- IPO Year
- EMN 1993
- RYTM 2017
- Fundamental
- Price
- EMN $64.05
- RYTM $99.02
- Analyst Decision
- EMN Buy
- RYTM Strong Buy
- Analyst Count
- EMN 14
- RYTM 13
- Target Price
- EMN $87.93
- RYTM $109.77
- AVG Volume (30 Days)
- EMN 1.6M
- RYTM 665.1K
- Earning Date
- EMN 10-30-2025
- RYTM 11-04-2025
- Dividend Yield
- EMN 5.18%
- RYTM N/A
- EPS Growth
- EMN N/A
- RYTM N/A
- EPS
- EMN 7.12
- RYTM N/A
- Revenue
- EMN $9,286,000,000.00
- RYTM $156,287,000.00
- Revenue This Year
- EMN N/A
- RYTM $46.10
- Revenue Next Year
- EMN $2.44
- RYTM $60.39
- P/E Ratio
- EMN $8.99
- RYTM N/A
- Revenue Growth
- EMN 1.52
- RYTM 53.55
- 52 Week Low
- EMN $56.78
- RYTM $45.91
- 52 Week High
- EMN $111.79
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- EMN 46.22
- RYTM 51.90
- Support Level
- EMN $61.48
- RYTM $95.88
- Resistance Level
- EMN $63.77
- RYTM $103.07
- Average True Range (ATR)
- EMN 1.71
- RYTM 3.13
- MACD
- EMN 0.04
- RYTM -0.19
- Stochastic Oscillator
- EMN 41.60
- RYTM 49.25
About EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.